Nicotine is metabolized into cotinine and then into trans-3=-hydroxycotinine, mainly by cytochrome P450 2A6. Recent studies reported better effectiveness of varenicline in women and in nicotine normal metabolizers phenotypically determined by nicotine-metabolite ratio. Our objective was to study the influence of nicotine-metabolite ratio, CYP2A6 genotype and sex on the response to nicotine replacement therapy and varenicline. Data were extracted from a longitudinal study which included smokers participating in a smoking cessation program. Response to treatment was defined by the absence of relapse when a set threshold of reduction in cigarettes per day relative to the week before the study was no more reached. The analysis considered total and partial reduction defined by a diminution of 100% and of 90% in cigarettes per day, respectively. The hazard ratio of relapsing was estimated in multivariate Cox regression models including the sex and the nicotine metabolism determined by the phenotype or by CYP2A6 genotyping (rs1801272 and rs28399433). In the normal metabolizers determined by phenotyping and in women, the hazard ratio for relapsing was significantly lower with varenicline for a partial decrease (HR ϭ 0. 
Public Health Significance
This study confirms that varenicline has better effectiveness than nicotine replacement therapy in nicotine normal metabolizers determined by the nicotine-metabolite ratio, and in women. The nicotine normal metabolizers determined by CYP2A6 rs1801272 genotyping also have greater response to varenicline than to nicotine replacement therapy. The choice of the smoking cessation pharmacological treatment should take into account nicotine metabolism and sex to obtain better abstinence rate in smokers.
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Smokers willing to stop smoking may be helped by a pharmacotherapy such as nicotine replacement therapy (NRT), bupropion, or varenicline. These three medications are used worldwide and several head-to-head effectiveness comparisons have been performed with mixed results. Varenicline has been associated with greater continuous abstinence rates than NRT after 52 weeks of follow-up (Aubin et al., 2008; Kralikova et al., 2013) . A multicenter study including 47 smoking cessation services concluded in a small advantage of varenicline over NRT combinations (i.e., any formulations such as gums, spray, and/or patches) although variations in population characteristics or clinical practice appear to influence the effectiveness of both therapies (Brose, West, & Stapleton, 2013) . A randomized parallel clinical trial in 272 subjects reported equivalent success between varenicline and nicotine patches at 1, 6, and 12 months of follow-up (Heydari, Talischi, Tafti, & Masjedi, 2012) , while a meta-analysis concluded that varenicline and combined NRT were equally effective in continuous or prolonged abstinence during at least 6 months (Cahill, Stevens, Perera, & Lancaster, 2013) .
In humans, nicotine is metabolized into cotinine and then into trans-3=-hydroxycotinine, mainly by cytochrome P450 (CYP) 2A6 (Messina, Tyndale, & Sellers, 1997; Nakajima et al., 1996) . The nicotine-metabolite ratio refers to the 3=-hydroxycotinine/cotinine ratio during smoking ad libitum, and is a marker of CYP2A6 activity. Interestingly, nicotine-metabolite ratio seems to be associated with 1-week abstinence, with nicotine slow metabolizers being more likely to achieve abstinence than normal metabolizers (odds ratio [OR] ϭ 1.32, 95% CI [1.05, 1.67]; p ϭ .019; Chenoweth et al., 2015) . Furthermore, a recent double-blind placebocontrolled trial reported that varenicline had greater effectiveness than NRT in nicotine normal metabolizers as determined by the nicotine-metabolite ratio (Lerman et al., 2015) .
Compared with CYP2A6 genotyping, nicotine-metabolite ratio has the advantage of taking into account both genetic and environmental (e.g., estrogen) effects on CYP2A6 activity (Dempsey et al., 2004; Lerman et al., 2015; Malaiyandi, Goodz, Sellers, & Tyndale, 2006; Schnoll et al., 2009 ). CYP2A6 activity is indeed induced by estradiol, leading to increased nicotine metabolism (Higashi et al., 2007) and women are more likely to be normal metabolizers than slow metabolizers (Chenoweth et al., 2014; Lerman et al., 2015) , especially when receiving estrogen-based hormonal therapy . The influence of sex on the effectiveness of smoking cessation treatment has been largely described. A meta-analysis of 14 studies comparing smoking cessation rate in men and women receiving nicotine patches reported a significantly lower rate of abstinence in women (Perkins & Scott, 2008) . Men were also found to have a significantly better abstinence rate with the combination varenicline-bupropion than with varenicline alone, whereas women had a similar response to both treatments (Potter, 2014; Rose & Behm, 2014) . It has therefore been suggested that women benefit more than men from varenicline alone and thus the addition of bupropion to varenicline would not improve the response in women (Gorelick, 2015; Rose & Behm, 2015) . Interestingly, varenicline compared with nicotine patches doubled the odds of abstinence at the end of a 4-week treatment in an exploratory short-term double-blind randomized trial among women smokers (Gray et al., 2015) . In a longer term, at 12 weeks, women had greater quit rates when receiving varenicline compared with NRT in a study involving almost 7,000 smokers (Walker et al., 2016) . Very recently a meta-analysis of 32 studies representing more than 14,000 smokers reported a greater efficacy in women taking varenicline compared with transdermal nicotine or bupropion. In men, no difference was shown between the three treatments (Smith et al., 2016) .
Several single nucleotide polymorphisms (SNP) in the CYP2A6 gene that affect enzyme activity have been characterized (Goodz & Tyndale, 2002; Mwenifumbo & Tyndale, 2007) . One of the most studied allele is the rs1801272 (479TϾA, Leu160His, CYP2A6 ‫ء‬ 2; Ray, Tyndale, & Lerman, 2009; Yamano, Tatsuno, & Gonzalez, 1990) . It leads to a predicted CYP2A6 activity between 40% and 50% of the normal activity, or less than 40% if two mutated alleles A are present (Malaiyandi et al., 2006) . Thus, individuals carrying one or two CYP2A6 ‫ء‬ 2 alleles are considered slow nicotine metabolizers (Benowitz, Swan, Jacob, Lessov-Schlaggar, & Tyndale, 2006) . Another common polymorphism, the rs28399433 (CYP2A6 ‫ء‬ 9, Ϫ48TϾG) located in the TATA box of the 5= flanking region of the CYP2A6 gene has been identified. The activity of the mutated TATA was reduced by 55% when compared with the wild allele and was shown to reduce mRNA expression and enzyme activity. (Haberl et al., 2005; Pitarque et al., 2001) .
The primary objective of our post hoc analysis of data from usual clinical care was to explore the influence of nicotine metabolism determined by the nicotine-metabolite ratio and of sex on the response to NRT and varenicline. Based on previous clinical trials (Gray et al., 2015; Lerman et al., 2015; Perkins & Scott, 2008) , we hypothesized that nicotine normal metabolizers and women would benefit more from varenicline. The second objective was to compare the influence of nicotine metabolism determined phenotypiThis document is copyrighted by the American Psychological Association or one of its allied publishers.
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cally by the nicotine-metabolite ratio and genetically by the CYP2A6 rs1801272 and rs28399433 polymorphisms on the response to NRT and varenicline.
Method Study Design and Participants
The original aim of this clinical and pharmacogenetic study was to examine the influence of smoking cessation on the activity of CYP1A2 isoform . For this purpose it included smokers from the general population wishing to participate in a smoking cessation program. This program offered a 3-month study period (five visits every week from Week 0 to Week 4, four visits every 2 weeks from Week 4 to Week 12) comprising smoking-cessation counseling and pharmacological treatment prescription (combined nicotine replacement therapies: patches, gums, and/or inhaler or varenicline) and a 6-month concluding visit. Details of the inclusion and exclusion criteria as well as clinical measures have been previously described . Blood sampling performed before the quit date was used to measure the nicotine-metabolite ratio. Abstinence was assessed during the follow-up by self-declaration and by measuring expired CO levels (Micro Smokerlyzer; Bedfont Scientific, Rochester, United Kingdom). Abstinence was confirmed if CO level was less than 10 parts per million (ppm). The number of cigarettes smoked between two visits was also recorded. The study was approved by the ethics committee of the Lausanne University Medical School and by the Swiss Agency for Therapeutic Products (Swissmedic, Bern, Switzerland). Written informed consent was obtained from all participants.
Treatment
After a counseling session with a clinician, participants chose to receive either varenicline or combined nicotine replacement therapies (patches, gums, and/or inhaler) in agreement with the clinician. NRT and varenicline were prescribed according to the manufacturers' information, to guidelines for smoking cessation PHS Guideline Update Panel, 2008 , and to patients' preferences. Main counterindications included cardiovascular diseases (unstable angina pectoris, recent myocardial infarction) or skin disorders (e.g., psoriasis, chronic dermatitis, urticaria) for NRT, and depression, past antidepressant treatments or other psychiatric diseases for varenicline. NRT formulations and dosing were chosen according to the nicotine dependence score measured by the Fagerström test for nicotine dependence (FTND) ranging from 0 to 10 (Heatherton, Kozlowski, Frecker, & Fagerstrom, 1991) . For instance, patients with a high dependence score (8 to 10) were prescribed with high concentration patches, combined with other NRT formulations (gums and/or inhaler). In patients with low dependence scores (0 to 3), one NRT formulation could be sufficient (low dose patches or gums/inhaler). NRT dosing was gradually decreased each month, for total treatment duration of 12 weeks. Varenicline was prescribed starting from 1 week before the quit date (0.5 mg once daily on Days 1-3 and 0.5 mg twice daily on Days 4 -7), then continued with 1 mg twice daily for a total of 12 weeks. The pharmacological treatment was proposed for 12 weeks free-of-charge and treatments were delivered at each visit.
Varenicline treatment but not combined NRT could be proposed for 12 supplementary weeks as recommended in the manufacturer's information.
If needed and with the approval of a clinician, a switch of treatment was allowed during the study. As the aim of the present study was to compare the effectiveness on smoking cessation of these two treatments, data from subjects who switched from one treatment group to another were excluded from the analysis (see Figure 1 ).
Nicotine-Metabolite Ratio
Cotinine and 3=-hydroxycotinine plasma levels were simultaneously measured by an ultra performance liquid chromatographytandem mass spectrometry method while participants were smoking ad libitum at the beginning of the study (Dobrinas, Choong et al., 2011) . Subjects were phenotypically considered slow metabolizers if nicotine-metabolite ratio was inferior to 0.26 and normal metabolizers if nicotine-metabolite ratio was higher or equal to 0.26 as previously described (Schnoll et al., 2009 ). The cut-off was set to the originally determined value of 0.26 in (Schnoll et al., 2009 ).
Genotyping
CYP2A6 SNPs were obtained using the CardioMetaboChip, a custom Illumina iSelect genotyping array designed to test DNA variation of over 200,000 SNPs from regions identified by large scale meta-analyses of genomewide association studies for metabolic and cardiovascular traits; 3,642 customized SNPs covering pharmacokinetic genes were added in the Cardiometabochip (Lubomirov, Csajka, & Telenti, 2007; Lubomirov et al., 2010) , among which eight SNPs from the CYP2A6 gene (rs5031016, rs8192730, rs1809810, rs1801272, rs28399453, rs28399454, rs28399433, rs2892625) . Four SNPs were excluded from analysis due to a very low minor allele frequencies (MAF Ͻ0.005) as reported in European population (rs5031016, rs8192730, rs1809810, rs28399454; Flicek et al., 2014) . The rs28399453 polymorphism is not reported to influence CYP2A6 activity and was thus excluded from analysis. Quality control excluded samples from the analysis if sex was inconsistent with genetic data from X-linked markers, genotype call rate less than 0.96 or Gene Call score less than 0.15. The SNP rs2892625 was excluded from analysis due to a Gene Call score Ͻ0.15. The two polymorphisms rs1801272 and rs28399433 were in Hardy Weinberg Equilibrium (p ϭ .68 and p ϭ .65, respectively) and were used for determining CYP2A6 genotype. In the sample analysis, individuals were homozygous nonmutated (TT) or heterozygous (TA) for the SNP rs1801272 and individuals were homozygous nonmutated (TT) or heterozygous (TG) for the SNP rs28399433. There were no homozygous mutated for any of the SNPs in the sample analysis. Subjects were classified as slow metabolizers if they were heterozygous for the SNPs rs1801272 or rs28399433, or for both SNPs according to results previously published Haberl et al., 2005; Pitarque et al., 2001 ). The homozygous nonmutated for both SNPs were defined as normal metabolizers. GenomeStudio Data Analysis Software was used to export results generated by Illumina CardioMetaboChip. This document is copyrighted by the American Psychological Association or one of its allied publishers.
Statistical Analysis
In this work, total smoking cessation and partial smoking reduction is used to evaluate response to nicotine replacement therapy or varenicline. Response to treatment was defined by the absence of relapse (i.e., when the reduction in cigarettes per day (CPD) consumption relative to the week before the study was not reached anymore).
Exploratory analysis for selection of thresholds. An exploratory analysis was first conducted to find the most appropriate threshold in CPD reduction defining partial smoking reduction. The week before the study and at each visit, participants self-reported the number of cigarettes per day or over the period between two visits. For nondaily smokers, the number of cigarettes smoked over the period between two visits was divided by the number of days of the period to calculate CPD. Overall, there was a concordance between the CPD and the CO levels recorded (r 2 ϭ 0.49, p Ͻ .01). For each subject and each visit the reduction in the number of CPD relative to the number of CPD the week before the study was calculated. A binary variable was defined as follows: status ϭ 0 if the threshold of CPD reduction was reached, status ϭ 1 if the threshold was not reached anymore (i.e., relapse). By varying the potential thresholds between 50% and 100% in the reduction of CPD, 51 variables status were coded for each subject at each visit. Then, for each threshold of reduction and each subject, a time-toevent variable was determined as the duration from the first visit when the threshold was reached to the time when the threshold was not reached anymore, or to the end of follow-up. Consequently, data from the visits during which the threshold was not already reached and participants who never reached the threshold were excluded from analysis (see Figure 1) . Fifty-one hazard-ratios (HR) representing the risk of relapse (for each one of 51 potential thresholds) were estimated to assess the effect of treatment (varenicline vs. nicotine replacement therapy) by adjusting for nicotine-metabolite ratio (slow metabolizers vs. normal metabolizers) and sex (men vs. women) in fitting a Cox proportional hazard regression model. HR and the 95% CI are presented in Figure S1 . With increasing threshold, the number of subjects included in each analysis decreased and the number of relapses increased. From 90% to 100% of CPD decrease, the 95% CI of the HR was the smallest, stable, and mostly below the value of 1. Two thresholds of reduction-the first one considering total abstinence: diminution of 100%, and the second one considering a partial reduc- This document is copyrighted by the American Psychological Association or one of its allied publishers.
tion of smoking: diminution of 90%, were therefore selected for further analysis. Relapse analysis for a total cessation and a partial reduction of CPD. Participants were considered as relapser if their reduction in CPD consumption became lower than the predefined threshold and as no relapser if they maintained the predefined threshold of CPD reduction during the overall period of follow-up. In the overall sample, chi-square tests evaluated the distributions of treatment group, nicotine metabolism (phenotypically determined by the nicotine-metabolite ratio) and sex among the relapsers and nonrelapsers as well as the distribution of the normal metabolizers and slow metabolizers among men and women. The cumulative probability of maintaining the selected threshold of CPD reduction by treatment group in the overall sample analysis was assessed using Kaplan-Meier survival analyses with subsequent Log-Rank tests.
Multivariate Cox proportional hazards regression models were carried out to obtain the HR of relapse and its 95% CI for the treatment (varenicline vs. NRT) in the overall sample and in subgroups: normal metabolizers, slow metabolizers, men, and women. The analyses were adjusted for nicotine-metabolite ratio, nicotine-metabolite ratio-by-treatment interaction, sex, age of onset for smoking and the number of CPD usually smoked in the overall sample. In normal and slow metabolizers, the analyses were adjusted for sex, age of onset for smoking, and the number of CPD usually smoked. In men and women, the adjustment was made by the nicotine-metabolite ratio, the nicotine-metabolite ratio-by-treatment interaction, the age of onset for smoking, and the number of CPD usually smoked. All statistical analyses were performed using the R software (v. 3.1.2, http://www.r-project .org). Results were considered statistically significant if p Յ .05 (two-tailed). Finally, with regards to the Cox regression, proportional hazard assumption was verified using the Grambsch Therneau test and results were satisfactory (Grambsch & Therneau, 1994) .
Influence of the genetically determined nicotine metabolism on the treatment response. To investigate the effect of nicotine metabolization effect on risk of relapse, the association of nicotine metabolism genetically determined (normal and slow metabolizers) versus the relapse status (relapser and nonrelapser) was first assessed using chi-square test. Then, the sample was stratified between normal metabolizers and slow metabolizers to obtain the HR of relapse and its 95% CI for the treatment (varenicline vs. NRT) in two subgroups using Cox proportional hazards regression models by adjusting for sex, age of onset for smoking and the number of CPD usually smoked.
Results

Study Participants and Analyzed Sample
Two-hundred and 11 smokers were recruited for a smoking cessation study and 194 subjects fulfilled the inclusion criteria; 153 and 164 participants were analyzed for the 100% (total cessation) and for the 90% (partial decrease) of CPD decrease, respectively (see Figure 1) .
Participants did not differ in any of the examined variables except in the age of onset for smoking with a lower age in the varenicline compared with the NRT group (see Table 1 ). In addition, in the analysis of a 90% of CPD decrease, the number of usually smoked CPD was significantly smaller in the NRT group than in the varenicline group (n ϭ 20 CPD and n ϭ 24 CPD respectively, p ϭ .03), but there was no significant difference in the number of smoked CPD the week before the study. Separate data between male and female are shown in Table S1 . Of note, the number of usually smoked cigarettes per day is significantly different between NRT and varenicline in males but not in females, which was taken into account in the statistical analysis. Although compliance cannot be ascertained, all participants were asked about the actual intake of varenicline or nicotine patches, gums, or inhalers at each visit.
When phenotypically determined, women were more likely to be normal metabolizers than slow metabolizers in the analyses for a 100% and a 90% of CPD decrease (Table 2 , p ϭ .03 and p ϭ .01, respectively).
Relapse Analysis for a Total Cessation and a Partial Reduction of CPD
For the decrease of 100% and 90%, relapse was significantly associated with the treatment (Table 3 , p ϭ .04 and p ϭ .02, respectively), NRT associated with more cases of relapse. The Kaplan-Meier estimate of the probability of maintaining the threshold was significantly higher for varenicline when compared with NRT for a 90% of CPD decrease ( Figure 2B , p ϭ .014). The estimate was also higher for varenicline but not significant for a 100% of CPD decrease (Figure 2A, p ϭ .054) .
The multivariate Cox regression predicted in the overall sample that participants treated with varenicline had a significant lower risk of relapse for a 90% of CPD decrease (Table 4, 
Comparison of the Influence of the Nicotine Metabolism Determined Either Phenotypically or Genetically on Treatment Response
The frequency of slow metabolizers was found to be much lower than the normal metabolizers when classifying participants according to CYP2A6 genotype as compared with the classification based on phenotype (see Table 1 ).These differences could probably be explained by the fact that classification based on phenotyping includes environmental factors, while genotyping was based on two SNPs only, whereas other mutations are possibly contributing to a slow metabolizer phenotype. This document is copyrighted by the American Psychological Association or one of its allied publishers.
For a partial decrease, the multivariate Cox regression predicted a similar significant lower risk of relapse with varenicline in the normal metabolizers determined by genotyping when compared with the normal metabolizers determined by phenotyping (Table 4, 
Discussion
It has recently been shown that nicotine normal metabolizers (phenotypically determined by the nicotine-metabolite ratio) have better quit rates with varenicline compared with nicotine patches (Lerman et al., 2015) . To our knowledge, the present study is the first to replicate this finding in usual clinical care data, using both phenotyping and genotyping tests. Varenicline response was superior to NRT in phenotype-based normal metabolizers in the case of a partial reduction. The finding that women smokers have higher response with varenicline over NRT for a partial reduction are in accordance with other recent findings (Gorelick, 2015; Gray et al., 2015; Rose & Behm, 2015) . The influence of sex in the effectiveness of the smoking cessation agent is now well acknowledged (McKee & Weinberger, 2015; Weinberger, Smith, Kaufman, & McKee, 2014) . Because CYP2A6 mRNA is induced by estradiol (Higashi et al., 2007) , women and especially premenopausal women may metabolize nicotine and cotinine faster than men . Supposedly, with nicotine being rapidly metabolized in women, the pharmacological effect of NRT on withdrawal symptoms is lower, which is in agreement with the reported lower success rate with nicotine Note. CPD ϭ cigarettes per day; NM ϭ normal metabolizer; SM ϭ slow metabolizer. a Phenotypically determined by the nicotine-metabolite ratio. b Chisquared test. This document is copyrighted by the American Psychological Association or one of its allied publishers.
patches (Perkins & Scott, 2008) . No difference was observed in treatment success in slow metabolizers and in men. Of note, in normal metabolizers genetically determined by the rs1801272 and rs28399433 mutations, the multivariate Cox regression model showed similar response to treatment for a partial CPD decrease compared with the same subgroup phenotypically determined. For a total abstinence, response to treatment was similar in normal metabolizers genetically or phenotypically determined, except a lack of statistical power in the analysis to observe a significant result in the phenotype-based normal metabolizers. The similarity of the result could be explained, at least in part, by the demonstrated influence of these mutations on CYP2A6 activity (Haberl et al., 2005; Malaiyandi et al., 2006; Pitarque et al., 2001 ). On the other hand, it can be assumed that the prediction of CYP2A6 activity based on nicotine-metabolite ratio is more accurate, as it integrates both genetic factors (taking into account all genetic variations and not only one mutation) and environmental factors (e.g., induction by estrogens).
In the overall sample analyzed, the probability of maintaining a diminution of 90% of smoked cigarettes per day over 6 months This article is intended solely for the personal use of the individual user and is not to be disseminated broadly.
was higher in the varenicline group than in the NRT group, while a trend was found when using a total abstinence as threshold. These results are not in agreement with the equivalent efficacy of varenicline and combined NRT reported in a meta-analysis (Cahill et al., 2013) comparing both treatments. It has to be stressed that the sample size in the present study was limited and the results should therefore be replicated. However, a special emphasis should be put on the selection of outcomes, which differ between the present and the meta-analysis (Cahill et al., 2013) : time during which a threshold of total cessation or partial reduction in CPD is maintained versus continuous or prolonged abstinence at least 6 months from the start of the treatment, respectively. In the present study, the analyses considered an absolute abstinence (reduction of 100%) as well as a partial reduction in CPD (90% reduction). Both thresholds gave essentially similar results. It should be mentioned that reduction in CPD consumption (instead of cessation) does not cancel health risks: A significantly higher risk of dying, especially from ischemic heart disease and lung cancer, was observed in men and women smoking one to four cigarettes per day compared with never-smokers (Bjartveit & Tverdal, 2005) . Thus, changes in CO and cotinine plasma levels consistently showed smaller reduction than CPD (Stead & Lancaster, 2007) due to the phenomenon of oversmoking: Smokers involuntarily increase the number and depth of inhalations from the remaining cigarettes to obtain the necessary nicotine quantity (Sadowski, Clair, & Cornuz, 2015) . This phenomenon is also observed in the present study: For the analysis of 90% of CPD decrease when compared with the NRT group, the number of usually smoked CPD is significantly lower in the varenicline group while there is no difference in cotinine and 3=-hydroxycotinine plasma levels. On the other hand, consumption reduction seems not to discourage smokers unmotivated to a project of total abstinence and can even encourage them when it is supported by NRT (Hughes & Carpenter, 2006; Stead & Lancaster, 2007) . Gradual reduction before the quit day appears to be associated with equivalent smoking cessation rates compared with abrupt cessation (Lindson-Hawley, Aveyard, & Hughes, 2012) . Sustained reduction was defined as reduction in 50% or more of the baseline reported cigarettes consumption in some industry sponsored trials (Moore et al., 2009) . In this work, when the reduction in cigarette consumption was below 90% of baseline, more subjects reached this objective, the number of relapses was lower and Cox regressions provided a very large HR 95% CI. We hypothesize that decreasing the cigarettes consumption by less than 90% of baseline value is a more feasible objective, leading to the difference between treatment responses being smaller with a large HR 95% CI.
Several limitations of the present study must be discussed. First, this clinical and pharmacogenetic study was not designed for the purpose of the present evaluation. However the valuable comparison of varenicline and NRT effectiveness by nicotine metabolism and sex obtained with clinical trials previously published deserved an investigation in the natural context of a smoking cessation program as proposed in tobacco consultation. Second, the analysis used a unique longitudinal dataset with rather small sample size per treatment group and no corrections for multiple testing were performed. Analyses should therefore be repeated in a larger cohort to confirm the influence of sex and nicotine metabolism on the response to varenicline and nicotine replacement therapy. However, the present findings are in agreement with a recently published study (Lerman et al., 2015) , and it is remarkable that similar results were obtained when examining the influence of CYP2A6 activity based both on phenotyping and genotyping methods. Third, this study was not randomized and it is not known whether the choice of the treatment by the participant could have an influence on the results. However, the significant difference in age of onset for smoking and in number of usually smoked cigarettes per day between the varenicline and the NRT group has been taking into account in the multivariate analysis by the correction with these two variables.
In summary, treatment of nicotine dependence is very challenging and can be hampered by the lack of motivation, environmental factors, or ineffective pharmacological treatment (Fiore & Baker, This document is copyrighted by the American Psychological Association or one of its allied publishers.
2011). In the present work, we showed that nicotine normal metabolizers are more likely to benefit from varenicline over NRT in usual clinical care data. Women who are reported to achieve a lower abstinence rate with NRT than men may have better success in smoking cessation with varenicline treatment. Future studies should also address the question on whether normal metabolizers and women would equally benefit, instead of varenicline, from higher nicotine doses. Because of the scarcity of existing data, our results contribute valuably to the extensive process of tailoring smoking cessation strategy.
